Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Lomitapide: navigating cardiovascular challenges with innovative therapies.
Mol Biol Rep
October 2024
College of Dental Medicine, Lincoln Memorial University, LMU tower, 1705 St. Mary Street, Knoxville, TN, 37917, USA.
Article Synopsis
- Dyslipidemia is a key risk factor for cardiovascular diseases, and current treatments primarily aim to lower LDL cholesterol levels to prevent conditions like atherosclerosis and myocardial infarction.
- Homozygous Familial Hypercholesterolemia (HoFH) results from mutations in the LDL receptor, leading to very high LDL cholesterol levels, which often do not respond well to standard statin therapy.
- Lomitapide, a microsomal triglyceride transfer protein inhibitor, has been approved for HoFH treatment; it effectively lowers LDL-C levels without affecting the LDL receptor and has been shown to reduce LDL-C by more than 50% in resistant cases.
Saroglitazar ameliorates 5- Fluorouracil-induced hepatorenal damage in rats.
Int Immunopharmacol
December 2024
Department of Pharmacology & Toxicology, Faculty of Pharmacy, Mansoura University, 35516, Mansoura, Egypt. Electronic address:
Rationale: Hepatotoxicity and nephrotoxicity are significant adverse effects caused in cancer patients treated with 5-Flurouracil (5-FU), a pyrimidine analogue anti-metabolite anticancer drug. The purpose of this research was to evaluate the impact of PPAR α/γ agonist (Saroglitazar; SARO) on 5-FU-induced hepatorenal damage in rats.
Methods: Male rats were randomly assigned to four groups: control, 5-FU, 5-FU + SARO (2 mg/kg), and 5-FU + SARO (4 mg/kg).
Saroglitazar suppresses KIM-1 and type IV collagen in high fat diet and low-dose streptozotocin-induced diabetic nephropathy in Wistar rats.
Iran J Basic Med Sci
January 2024
Department of Pharmacology, School of Pharmaceutical Education & Research (SPER), Jamia Hamdard, New Delhi-110062, India.
Objectives: Nephropathy is the most common comorbidity linked to T2D. The present study aimed to examine the potential of saroglitazar in the context of a high-fat diet and low-dose streptozotocin-induced diabetic nephropathy in Wistar rats.
Materials And Methods: Molecular docking simulation investigations were conducted on the ligand-binding region of type IV collagen and Kidney injury molecule-1 (KIM-1), using saroglitazar and fenofibrate as the subjects.
Saroglitazar, a PPAR α/γ agonist alleviates 3-Nitropropionic acid induced neurotoxicity in rats: Unveiling the underlying mechanisms.
Neurotoxicology
December 2024
Department of Pharmacology, Shri Vishnu College of Pharmacy (SVCP), Vishnupur, Bhimavaram, West Godavari, Andhra Pradesh 534202, India. Electronic address:
Saroglitazar (SGZ), a peroxisomal proliferated activated receptor α/γ agonist showed neuroprotective effects in various neurodegenerative disorders like Alzheimer's and Parkinson's. However, no studies were performed on Huntington's, so the goal of the current study is to examine the effect of SGZ on Huntington's disease like symptoms induced by 3-Nitropropionic acid. In this protocol, twenty-four rats were divided into four groups, each group consisting of 6 animals.
View Article and Find Full Text PDFSaroglitazar Enhances Memory Functions and Adult Neurogenesis via Up-Regulation of Wnt/β Catenin Signaling in the Rat Model of Dementia.
ACS Chem Neurosci
October 2024
Amity Institute of Microbial Technology, Amity University, Noida, Uttar Pradesh 201313, India.
Peroxisome proliferator-activated receptors (PPARs) have emerged as a promising target for the treatment of various neurodegenerative disorders. Studies have shown that both PPAR α & γ individually modulate various pathophysiological events like neuroinflammation and insulin resistance, which are known to variedly affect neurogenesis. Our study aimed to evaluate the effect of saroglitazar (SGZR), a dual PPAR agonist, on adult neurogenesis and spatial learning and memory, in intracerebroventricular streptozotocin (ICV STZ)-induced dementia in rats.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!